The stellar performance of Sonova’s hearing aid business significantly offset ongoing challenges faced by its cochlear implant division, particularly within the crucial markets of the United States and China. Bolstered by these stronger-than-anticipated overall results, the company has proactively revised its financial outlook, raising its expectations for both sales and profit growth for the remainder of its fiscal year, signaling confidence in its continued trajectory.
Phonak Innovation and Market Leadership Fuel Hearing Instruments Division
At the heart of Sonova’s exceptional first-half results was its Hearing Instruments division, a powerhouse encompassing both the manufacturing of hearing aids and its extensive network of retail hearing care operations. This division alone generated CHF 1.72 billion (approximately $2.05 billion USD) in sales during the six-month period, marking an impressive 9.0% increase in local currencies. This growth trajectory highlights the sustained demand for Sonova’s cutting-edge hearing aid technologies and its strategic market penetration.
A granular look into the division’s performance reveals a particularly strong showing in its wholesale business, which serves hearing care professionals, distributors, and other commercial partners. Sales in this segment surged by 11.0%, reflecting robust commercial relationships and the successful introduction of new products. Concurrently, Sonova’s retail hearing care business, which provides direct services to end-users, also demonstrated healthy growth of 6.5%. According to Sonova, its wholesale hearing aid business has now achieved an extraordinary feat, gaining market share for an eleventh consecutive quarter. This consistent market share expansion is a testament to the enduring appeal and technological superiority of its product offerings, as well as its proactive engagement with key commercial channels.
Much of this growth can be directly attributed to the success of Phonak’s recent portfolio of hearing technologies. Products such as the Virto R and Infinio Ultra continued to drive sales, captivating consumers with their innovative features and performance. A significant catalyst for growth towards the end of the reporting period was the highly anticipated introduction of the new Phonak Audéo EON platform. This revolutionary platform, building on Sonova’s legacy of innovation, incorporates updated artificial intelligence-based sound processing capabilities within a remarkably smaller and lighter hearing aid design. The company specifically highlighted several key enhancements delivered by the EON platform, including significant improvements in speech understanding, seamless connectivity options, advanced wind noise management, and superior battery performance, all of which contribute to an unparalleled user experience.
Eric Bernard, CEO of Sonova, underscored the company’s commitment to innovation and its direct impact on market success. "Our innovation leadership is delivering meaningful advances in hearing performance and experience with EON, Roger On Sphere and Integro," Bernard stated. "EON is already contributing above our expectations, combining superior acoustics in a smaller device with best-in-class connectivity – its launch across our markets supported growth and market share gains." This statement from the CEO provides critical insight into the strategic importance of the EON platform and its immediate positive reception in the market.
Beyond the Audéo EON, Sonova also emphasized the strong contribution of its Roger On Sphere, a state-of-the-art remote microphone technology. Designed to significantly enhance speech understanding across varying distances and in complex, noisy environments involving multiple speakers, Roger On Sphere complements the core hearing aid offerings by providing targeted assistance in challenging listening situations, further solidifying Phonak’s reputation for comprehensive hearing solutions.
Geographic Expansion and Critical North American Demand

Geographically, North America continued to be a pivotal engine for Sonova’s robust performance, with regional sales escalating by 7.5% in local currencies to reach CHF 654.3 million (approximately $779 million USD). This growth was primarily propelled by strong hearing aid sales, fueled by increased demand from major commercial customers and, notably, a significant uptick in deliveries to the U.S. Department of Veterans Affairs (VA). The VA represents an exceptionally vital market for hearing aid manufacturers due to the vast number of veterans who receive comprehensive hearing healthcare services through the federal system. Sonova’s ability to secure and expand its presence within this critical segment speaks volumes about the quality and reliability of its products, as well as its strategic governmental relationships.
The global hearing aid market, estimated by Sonova to have grown approximately 5% during the first half of its financial year, with an acceleration noted in the second quarter, underscores a healthy industry environment. Sonova’s performance, outpacing this market average, indicates a capturing of market share and a strong competitive edge.
Beyond North America, Sonova reported impressive growth across other key regions. Sales in Asia Pacific surged by an outstanding 11.4%, propelled by vigorous demand for hearing aids in economically significant markets such as Australia, China, and Japan. Europe and Latin America also contributed positively to the company’s overall geographic diversification and revenue streams.
Sonova’s strategic expansion also extended to its retail hearing care operations through targeted acquisitions. The company successfully integrated Harbor Audiology, a reputable hearing care provider based in Washington State, into its network. Furthermore, the acquisition of Hørservice Danmark, a Danish provider specializing in innovative mobile hearing care services, reflects Sonova’s forward-thinking approach to service delivery and its commitment to meeting evolving consumer needs through accessible and convenient care models. These acquisitions not only expand Sonova’s direct-to-consumer reach but also provide valuable insights into market trends and patient preferences.
Cochlear Implants Division Navigates Headwinds and Anticipates Future Growth
While the hearing aid segment soared, Sonova’s Advanced Bionics cochlear implant business faced a more challenging first half of the fiscal year. Sales within the Cochlear Implants division experienced a decline of 10.2% in local currencies, totaling CHF 117.4 million (approximately $140 million USD). The company primarily attributed this downturn to lower cochlear implant system sales in two crucial markets: China and the United States. Additionally, reduced sales of processor upgrades and accessories contributed to the divisional challenges.
In China, the landscape for medical device sales has been impacted by evolving government purchasing arrangements, which have introduced new pressures on cochlear implant sales. In the United States and other markets, Sonova noted that some customers strategically delayed processor upgrades, a common phenomenon in the technology sector, as they awaited the introduction of newer, more advanced technology. This delay, while impacting current sales, often foreshadows a surge in demand once the new products become widely available.
Looking ahead, Advanced Bionics introduced its Integro cochlear implant sound processor in Europe in October 2026, following successful regulatory approval. This next-generation processor is poised to redefine the cochlear implant experience, incorporating Phonak AI-based technology, significantly improved sound localization capabilities, and seamless Roger connectivity. The U.S. introduction of the Integro processor remains subject to the rigorous approval processes of the Food and Drug Administration (FDA), a critical milestone that, once achieved, is expected to invigorate the American market.
Despite the overall decline in the division, there were pockets of growth, with Sonova reporting increased cochlear implant sales in several markets, including Canada, Brazil, India, and various parts of Europe. These regional successes demonstrate the underlying demand and the potential for future recovery and growth once the new technologies gain broader regulatory and market acceptance.
Enhanced Profitability and an Elevated Financial Outlook

Beyond top-line growth, Sonova also reported significantly improved profitability during the first half of the fiscal year. This enhanced financial health reflects a confluence of factors, including the increased volume of hearing aid sales, the realization of higher average selling prices for its premium products, and disciplined efforts to manage operating costs across its global operations.
Core operating profit, a key measure of earnings derived from the company’s ongoing business activities and excluding certain exceptional expenses, saw a remarkable increase of 22.9% in local currencies, reaching CHF 384 million (approximately $457 million USD). This substantial improvement in operational efficiency and profitability underscores Sonova’s robust financial management and its ability to translate strong sales into meaningful earnings.
The impressive first-half performance and improved profitability prompted Sonova to confidently raise its financial outlook for the entire 2026/27 fiscal year. The company now anticipates overall sales growth of 6% to 8% in local currencies, an upward revision from its previous forecast of 5% to 8%. Furthermore, it has elevated its projection for core operating profit, now expecting an increase of 10% to 13%, up from its earlier forecast of 7% to 10%. These revised forecasts, measured in local currencies, indicate a strong belief within Sonova’s leadership that the positive momentum will continue throughout the fiscal year.
In conjunction with its internal forecasts, Sonova also revised its estimate for overall global hearing aid market growth during the financial year, raising it to 3% to 5% from its previous expectation of 2% to 4%. This optimistic revision reflects broader positive trends in the hearing healthcare industry, driven by demographic shifts, increased awareness, and continuous technological advancements.
Strategic Divestment and Focused Future
In a separate but strategically important development, Sonova confirmed that its planned divestment of its Consumer Hearing business remains on track for completion during the 2026/27 financial year. This business segment, which includes consumer audio products, is being strategically separated from Sonova’s core hearing healthcare operations. This divestment is a clear strategic move to streamline Sonova’s portfolio, allowing the company to concentrate its resources, innovation, and market efforts squarely on its foundational and high-growth hearing healthcare divisions, encompassing both hearing aids and cochlear implants. This focus is expected to enhance operational efficiency, foster deeper specialization, and ultimately reinforce Sonova’s leadership in the medical hearing technology space.
Broader Implications and Industry Context
Sonova’s strong performance in the first half of 2026/27 provides a compelling narrative of resilience and strategic execution within the global hearing healthcare industry. The company’s ability to consistently gain market share, particularly in the competitive wholesale hearing aid segment, points to the efficacy of its innovation pipeline and its strong relationships with hearing care professionals worldwide. The success of products like the Phonak Audéo EON and Roger On Sphere highlights the critical role of AI-driven advancements and enhanced connectivity in meeting the evolving needs of individuals with hearing loss.
The challenges faced by the cochlear implant division, while temporary, underscore the complexities of navigating diverse regulatory environments and consumer upgrade cycles in high-tech medical fields. However, the impending U.S. launch of the Integro cochlear implant processor offers significant potential for a turnaround in this segment, as new technology often revitalizes demand.
With an aging global population and increasing awareness about the importance of addressing hearing loss, the demand for hearing solutions is projected to continue its upward trajectory. Sonova, with its robust financial position, clear strategic direction, and unwavering commitment to innovation, appears exceptionally well-positioned to capitalize on these demographic and market trends. The raised full-year guidance not only instills confidence in investors but also signals Sonova’s continued ambition to lead the industry, driving advancements that improve the lives of millions worldwide. The strategic divestment further sharpens this focus, ensuring that Sonova remains agile and concentrated on its core mission of delivering unparalleled hearing solutions.
